Загрузка...
Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
BACKGROUND: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a novel class of pharmacotherapeutics for type 2 diabetes management that work by reducing renal reabsorption of glucose. Ipragliflozin is a potent, selective SGLT-2 inhibitor used for the management of type 2 diabetes. OBJECTIVE: Th...
Сохранить в:
| Опубликовано в: : | Drug Des Devel Ther |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8286902/ https://ncbi.nlm.nih.gov/pubmed/34285473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S281602 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|